Shots:

• The study involves assessing of calcineurin-free treatment with iscalimab vs tacrolimus to test the durability of transplanted kidney grafts and improve long-term outcomes for kidney transplant patients
• The study resulted in 60% normal kidney histology@1 year for iscalimab-treated transplant patients with lower chronic allograft damage index (CADI) scores- Presented at American Transplant Congress (ATC) 2019
• Iscalimab is a mAb that prevents CD40 pathway signaling- further activates CD40+ cell types and is currently evaluated in P-IIb trial (Cirrus I- NCT03663335)

Ref: Novartis | Image: Xtra Shot